Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Basit Öğe Kaydı
dc.authoridAkin Telli, Tugba/0000-0001-6535-6030
dc.authoridbilgin, burak/0000-0003-1717-8246
dc.authoridGOKER, ERDEM/0000-0001-6180-713X
dc.authoridGursoy, Pinar/0000-0003-1392-6753
dc.authoridSAKIN, Abdullah/0000-0003-2538-8569
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.authorwosidmenekşe, serkan/HNP-3265-2023
dc.authorwosidAkin Telli, Tugba/GSE-4006-2022
dc.authorwosidbilgin, burak/A-9416-2018
dc.authorwosidmustafa, Muhammed/HME-1300-2023
dc.authorwosidtopcu, atakan/HKE-0758-2023
dc.authorwosidCelik, Emir/GRF-6617-2022
dc.authorwosidErdogan, Atike Pinar/AFC-3012-2022
dc.contributor.authorGursoy, Pinar
dc.contributor.authorTatli, Ali Murat
dc.contributor.authorErdem, Dilek
dc.contributor.authorGoker, Erdem
dc.contributor.authorCelik, Emir
dc.contributor.authorDemirci, Nebi Serkan
dc.contributor.authorSakin, Abdullah
dc.contributor.authorAkyol, Murat
dc.date.accessioned2023-03-22T19:47:34Z
dc.date.available2023-03-22T19:47:34Z
dc.date.issued2022
dc.departmentBelirleneceken_US
dc.description.abstractObjectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p = 0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p = 0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p = 0.323). Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.en_US
dc.identifier.doi10.1007/s00432-022-03984-5
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.pmid35381885en_US
dc.identifier.scopus2-s2.0-85127494466en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-022-03984-5
dc.identifier.urihttps://hdl.handle.net/20.500.14034/772
dc.identifier.wosWOS:000779481900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.journalJournal Of Cancer Research And Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectExon 18en_US
dc.subjectExon 20en_US
dc.subjectErlotiniben_US
dc.subjectAfatiniben_US
dc.subjectNSCLCen_US
dc.subjectGrowth-Factor Receptoren_US
dc.subjectTyrosine Kinase Inhibitoren_US
dc.subject1st-Line Treatmenten_US
dc.subjectOpen-Labelen_US
dc.subjectMulticenteren_US
dc.subjectEfficacyen_US
dc.subjectChemotherapyen_US
dc.titleReal-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations a Turkish Oncology Group (TOG) study.pdf
Boyut:
1.03 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin / Full text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu